Cipher Current Deferred Revenue vs Cash And Short Term Investments Analysis

CPH Stock

CAD 14.40 0.16 1.12%

Cipher Pharmaceuticals financial indicator trend analysis is way more than just evaluating Cipher Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cipher Pharmaceuticals is a good investment. Please check the relationship between Cipher Pharmaceuticals Current Deferred Revenue and its Cash And Short Term Investments accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cipher Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

Current Deferred Revenue vs Cash And Short Term Investments

Current Deferred Revenue vs Cash And Short Term Investments Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cipher Pharmaceuticals Current Deferred Revenue account and Cash And Short Term Investments. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Cipher Pharmaceuticals' Current Deferred Revenue and Cash And Short Term Investments is -0.27. Overlapping area represents the amount of variation of Current Deferred Revenue that can explain the historical movement of Cash And Short Term Investments in the same time period over historical financial statements of Cipher Pharmaceuticals, assuming nothing else is changed. The correlation between historical values of Cipher Pharmaceuticals' Current Deferred Revenue and Cash And Short Term Investments is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Current Deferred Revenue of Cipher Pharmaceuticals are associated (or correlated) with its Cash And Short Term Investments. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Cash And Short Term Investments has no effect on the direction of Current Deferred Revenue i.e., Cipher Pharmaceuticals' Current Deferred Revenue and Cash And Short Term Investments go up and down completely randomly.

Correlation Coefficient

-0.27

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Current Deferred Revenue

Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of Cipher Pharmaceuticals balance sheet. This account contains Cipher Pharmaceuticals investments that will expire within one year. These investments include stocks and bonds that can be liquidated by Cipher Pharmaceuticals fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most indicators from Cipher Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cipher Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cipher Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

At this time, Cipher Pharmaceuticals' Selling General Administrative is very stable compared to the past year. As of the 27th of November 2024, Discontinued Operations is likely to grow to about 196.8 K, though Tax Provision is likely to grow to (7.3 M).

	2021	2022	2023	2024 (projected)
Gross Profit	18.3M	16.7M	17.1M	16.3M
Total Revenue	21.9M	20.7M	21.2M	18.1M

Gross Profit Total Revenue

Cipher Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Non Current Liabilities Total	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Intangible Assets
Total Assets		0.64	0.37	0.54	0.59	-0.11	-0.46	-0.02	0.58	0.46	0.66	0.8	0.28	0.57	0.66	0.36	0.24	0.61	0.52	0.62	-0.51	0.65	-0.07	0.84	0.59	0.61
Short Long Term Debt Total	0.64		0.69	0.61	-0.07	-0.08	-0.29	0.56	0.09	0.53	0.29	0.47	0.39	0.03	0.29	0.43	-0.13	0.99	0.01	0.86	-0.07	0.94	-0.12	0.54	0.97	0.85
Other Current Liab	0.37	0.69		0.84	-0.3	-0.05	-0.4	0.53	-0.02	0.65	0.17	0.07	0.41	-0.16	0.17	0.6	-0.16	0.7	-0.15	0.52	-0.12	0.84	-0.09	0.49	0.65	0.38
Total Current Liabilities	0.54	0.61	0.84		-0.05	-0.05	-0.38	0.45	0.22	0.76	0.22	0.3	0.28	-0.04	0.22	0.73	-0.07	0.6	-0.01	0.57	-0.4	0.82	-0.09	0.58	0.54	0.46
Total Stockholder Equity	0.59	-0.07	-0.3	-0.05		-0.05	-0.3	-0.68	0.74	-0.03	0.75	0.71	0.15	0.92	0.75	-0.09	0.37	-0.11	0.89	-0.03	-0.54	-0.13	0.02	0.44	-0.06	0.03
Property Plant And Equipment Net	-0.11	-0.08	-0.05	-0.05	-0.05		-0.26	0.15	-0.11	-0.35	-0.24	0.0	-0.26	-0.23	-0.24	-0.12	-0.12	-0.14	-0.13	-0.07	-0.22	-0.11	0.99	-0.19	0.0	-0.05
Current Deferred Revenue	-0.46	-0.29	-0.4	-0.38	-0.3	-0.26		-0.06	-0.42	-0.09	-0.27	-0.47	0.16	-0.29	-0.27	-0.04	-0.27	-0.22	-0.49	-0.23	0.51	-0.3	-0.28	-0.29	-0.39	-0.16
Net Debt	-0.02	0.56	0.53	0.45	-0.68	0.15	-0.06		-0.3	0.25	-0.6	0.01	-0.03	-0.69	-0.6	0.28	-0.31	0.55	-0.57	0.64	0.09	0.59	0.07	-0.21	0.59	0.62
Retained Earnings	0.58	0.09	-0.02	0.22	0.74	-0.11	-0.42	-0.3		0.36	0.48	0.69	0.07	0.71	0.48	0.3	0.3	0.03	0.8	0.14	-0.87	0.08	-0.07	0.38	0.08	0.16
Accounts Payable	0.46	0.53	0.65	0.76	-0.03	-0.35	-0.09	0.25	0.36		0.31	0.13	0.41	0.07	0.31	0.92	-0.13	0.55	-0.03	0.52	-0.32	0.68	-0.37	0.63	0.39	0.4
Cash	0.66	0.29	0.17	0.22	0.75	-0.24	-0.27	-0.6	0.48	0.31		0.47	0.49	0.84	1.0	0.17	0.22	0.3	0.7	0.1	-0.26	0.26	-0.19	0.79	0.24	0.07
Non Current Assets Total	0.8	0.47	0.07	0.3	0.71	0.0	-0.47	0.01	0.69	0.13	0.47		0.16	0.62	0.47	0.03	0.26	0.41	0.7	0.56	-0.58	0.39	0.03	0.39	0.52	0.63
Non Currrent Assets Other	0.28	0.39	0.41	0.28	0.15	-0.26	0.16	-0.03	0.07	0.41	0.49	0.16		0.3	0.49	0.25	-0.3	0.42	0.14	0.23	0.04	0.39	-0.26	0.41	0.32	0.21
Other Assets	0.57	0.03	-0.16	-0.04	0.92	-0.23	-0.29	-0.69	0.71	0.07	0.84	0.62	0.3		0.84	-0.04	0.47	0.0	0.89	-0.07	-0.44	-0.05	-0.16	0.51	0.02	-0.03
Cash And Short Term Investments	0.66	0.29	0.17	0.22	0.75	-0.24	-0.27	-0.6	0.48	0.31	1.0	0.47	0.49	0.84		0.17	0.22	0.3	0.7	0.1	-0.26	0.26	-0.19	0.79	0.24	0.07
Net Receivables	0.36	0.43	0.6	0.73	-0.09	-0.12	-0.04	0.28	0.3	0.92	0.17	0.03	0.25	-0.04	0.17		-0.15	0.45	-0.19	0.46	-0.35	0.61	-0.16	0.56	0.27	0.33
Common Stock Shares Outstanding	0.24	-0.13	-0.16	-0.07	0.37	-0.12	-0.27	-0.31	0.3	-0.13	0.22	0.26	-0.3	0.47	0.22	-0.15		-0.15	0.36	-0.17	-0.23	-0.13	-0.07	0.14	-0.1	-0.13
Non Current Liabilities Total	0.61	0.99	0.7	0.6	-0.11	-0.14	-0.22	0.55	0.03	0.55	0.3	0.41	0.42	0.0	0.3	0.45	-0.15		-0.05	0.86	0.01	0.94	-0.17	0.55	0.95	0.83
Inventory	0.52	0.01	-0.15	-0.01	0.89	-0.13	-0.49	-0.57	0.8	-0.03	0.7	0.7	0.14	0.89	0.7	-0.19	0.36	-0.05		-0.08	-0.59	-0.08	-0.06	0.33	0.07	-0.02
Other Current Assets	0.62	0.86	0.52	0.57	-0.03	-0.07	-0.23	0.64	0.14	0.52	0.1	0.56	0.23	-0.07	0.1	0.46	-0.17	0.86	-0.08		-0.09	0.84	-0.11	0.4	0.84	0.97
Other Stockholder Equity	-0.51	-0.07	-0.12	-0.4	-0.54	-0.22	0.51	0.09	-0.87	-0.32	-0.26	-0.58	0.04	-0.44	-0.26	-0.35	-0.23	0.01	-0.59	-0.09		-0.13	-0.25	-0.31	-0.06	-0.1
Total Liab	0.65	0.94	0.84	0.82	-0.13	-0.11	-0.3	0.59	0.08	0.68	0.26	0.39	0.39	-0.05	0.26	0.61	-0.13	0.94	-0.08	0.84	-0.13		-0.15	0.62	0.88	0.77
Property Plant And Equipment Gross	-0.07	-0.12	-0.09	-0.09	0.02	0.99	-0.28	0.07	-0.07	-0.37	-0.19	0.03	-0.26	-0.16	-0.19	-0.16	-0.07	-0.17	-0.06	-0.11	-0.25	-0.15		-0.16	-0.03	-0.08
Total Current Assets	0.84	0.54	0.49	0.58	0.44	-0.19	-0.29	-0.21	0.38	0.63	0.79	0.39	0.41	0.51	0.79	0.56	0.14	0.55	0.33	0.4	-0.31	0.62	-0.16		0.42	0.32
Short Term Debt	0.59	0.97	0.65	0.54	-0.06	0.0	-0.39	0.59	0.08	0.39	0.24	0.52	0.32	0.02	0.24	0.27	-0.1	0.95	0.07	0.84	-0.06	0.88	-0.03	0.42		0.84
Intangible Assets	0.61	0.85	0.38	0.46	0.03	-0.05	-0.16	0.62	0.16	0.4	0.07	0.63	0.21	-0.03	0.07	0.33	-0.13	0.83	-0.02	0.97	-0.1	0.77	-0.08	0.32	0.84

Click cells to compare fundamentals

Cipher Pharmaceuticals Account Relationship Matchups

Cipher Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	46.5M	44.3M	51.7M	73.8M	86.0M	46.4M
Short Long Term Debt Total	9.6M	1.8M	516K	428K	353K	335.4K
Other Current Liab	4.5M	5.2M	450K	257K	295.6K	280.8K
Total Current Liabilities	16.6M	9.9M	12.3M	9.4M	5.3M	10.3M
Total Stockholder Equity	28.0M	32.6M	38.9M	64.1M	80.5M	84.5M
Property Plant And Equipment Net	2.2M	1.9M	501K	481K	402K	640.4K
Current Deferred Revenue	274K	307K	450K	257K	519K	714.3K
Net Debt	3.2M	(7.3M)	(20.0M)	(28.4M)	(39.5M)	(37.5M)
Retained Earnings	13.9M	18.4M	25.2M	50.5M	66.3M	69.6M
Accounts Payable	4.1M	1.6M	5.6M	4.1M	4.6M	5.6M
Cash	6.3M	9.1M	20.5M	28.8M	39.8M	41.8M
Non Current Assets Total	29.2M	24.1M	22.3M	35.6M	37.8M	39.6M
Non Currrent Assets Other	(28.3M)	(21.8M)	(19.9M)	(18.9M)	19.9M	20.9M
Other Assets	943K	2.4M	2.5M	16.7M	19.2M	20.1M
Cash And Short Term Investments	6.3M	9.1M	20.5M	28.8M	39.8M	41.8M
Net Receivables	8.9M	9.2M	6.7M	6.8M	5.1M	8.6M
Common Stock Shares Outstanding	27.0M	27.4M	26.8M	107.5M	25.4M	32.1M
Liabilities And Stockholders Equity	46.5M	44.3M	51.7M	73.8M	86.0M	46.4M
Non Current Liabilities Total	1.8M	1.7M	460K	327K	259K	246.1K
Inventory	1.0M	892K	1.7M	2.2M	3.0M	3.1M
Other Current Assets	963.0K	875K	471K	371K	378K	359.1K
Other Stockholder Equity	5.0M	5.1M	5.1M	5.4M	5.8M	5.5M
Total Liab	18.4M	11.6M	12.8M	9.7M	5.5M	5.2M
Property Plant And Equipment Gross	2.2M	1.9M	641K	716K	756K	686.7K
Total Current Assets	17.2M	20.1M	29.3M	38.2M	48.3M	27.9M
Short Term Debt	7.7M	137K	56K	101K	94K	89.3K
Intangible Assets	10.4M	4.2M	3.6M	2.8M	1.8M	1.7M
Common Stock	18.7M	18.7M	18.1M	17.7M	18.0M	14.7M
Other Liab	1.2M	19K	8K	5K	4.5K	4.3K
Net Tangible Assets	1.9M	12.8M	19.5M	45.6M	41.1M	43.1M
Property Plant Equipment	2.2M	1.9M	501K	481K	553.2K	788.2K
Long Term Debt Total	1.8M	1.7M	460K	327K	294.3K	279.6K
Capital Surpluse	5.0M	5.1M	5.1M	5.4M	6.2M	5.6M
Net Invested Capital	35.6M	32.6M	38.9M	64.1M	80.5M	52.7M
Net Working Capital	615K	10.2M	17.0M	28.8M	43.0M	45.2M

Pair Trading with Cipher Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cipher Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cipher Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Moving against Cipher Stock

0.59	CHE-UN	Chemtrade Logistics	Pair Corr
0.53	BOFA	Bank of America	Pair Corr
0.52	RY-PS	Royal Bank Earnings Call This Week	Pair Corr
0.48	RY	Royal Bank Earnings Call This Week	Pair Corr
0.47	RY-PN	Royal Bank Earnings Call This Week	Pair Corr

The ability to find closely correlated positions to Cipher Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cipher Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cipher Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cipher Pharmaceuticals to buy it.

The correlation of Cipher Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cipher Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cipher Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cipher Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

Other Information on Investing in Cipher Stock

Balance Sheet is a snapshot of the financial position of Cipher Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Cipher Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Cipher Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Cipher currently owns. An asset can also be divided into two categories, current and non-current.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cipher Current Deferred Revenue vs Cash And Short Term Investments Analysis

Current Deferred Revenue vs Cash And Short Term Investments

Current Deferred Revenue vs Cash And Short Term Investments Correlation Analysis

Correlation Coefficient

Current Deferred Revenue

Cash And Short Term Investments

Cipher Pharmaceuticals fundamental ratios Correlations

Cipher Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cipher Pharmaceuticals fundamental ratios Accounts

Pair Trading with Cipher Pharmaceuticals

Moving against Cipher Stock

Other Information on Investing in Cipher Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Non Current Liabilities Total	+ 0.99	Short Long Term Debt Total
Property Plant And Equipment Gross	+ 0.99	Property Plant And Equipment Net
Short Term Debt	+ 0.97	Short Long Term Debt Total
Intangible Assets	+ 0.97	Other Current Assets
Short Term Debt	+ 0.95	Non Current Liabilities Total

Other Stockholder Equity	- 0.87	Retained Earnings
Other Assets	- 0.69	Net Debt
Net Debt	- 0.68	Total Stockholder Equity
Cash And Short Term Investments	- 0.6	Net Debt
Cash	- 0.6	Net Debt
Other Stockholder Equity	- 0.59	Inventory